STOCK TITAN
  1. Home
  2. News
  3. RGEN

Repligen Corp. - RGEN STOCK NEWS

Welcome to our dedicated news page for Repligen (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Repligen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Repligen's position in the market.

News
Repligen to Report First Quarter 2024 Financial Results
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will report its first quarter 2024 financial results on May 1, 2024. A conference call and webcast will be held to discuss business updates and financial results for the reporting period ended March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Repligen Appoints Maggie A. Pax to Board of Directors
Rhea-AI Summary
Repligen (NASDAQ:RGEN) appoints Maggie A. Pax to its Board of Directors, expanding the board to nine members. Ms. Pax brings over 25 years of experience in leading growth strategies for global companies, including roles at Thermo Fisher Scientific. Repligen's leadership team welcomes her extensive industry expertise, strategic planning skills, and innovation focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
management
-
News
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Repligen Corporation (RGEN) reports fourth quarter revenue of $156 million and full year revenue of $639 million. The company highlights positive momentum in new modalities, closed acquisition of Metenova AB, launched TangenX® SC, and published a Sustainability report. Financially, RGEN's Q4 2023 saw a decrease in total revenue and gross profit compared to 2022, with a loss from operations and net loss. The company's cash position improved to $751.3 million. RGEN provides financial guidance for FY 2024 with expected revenue of $620M - $650M and adjusted net income of $80M - $84M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
earnings
News
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Repligen Corporation (RGEN) will report its fourth quarter 2023 financial results on February 21, 2024. A conference call and webcast will be held to discuss business updates and financial results for the reporting periods. The call will be accessible by dialing toll-free for domestic and international callers, and a webcast will be available via the Investor Relations section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences earnings
-
News
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) to present at 42nd Annual J.P. Morgan Healthcare conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences
-
News
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
Rhea-AI Summary
Repligen Corporation (NASDAQ: RGEN) announced entering into exchange and/or subscription agreements to issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028, with a conversion premium of approximately 30% over the closing price of Repligen’s common stock on December 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
none
News
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) announced the digital publication of its 2022 Sustainability Report, emphasizing progress across environmental, social, and governance (ESG) initiatives, with disclosures against GRI, SASB, UN SDGs, and TCFD frameworks. The report highlights a 40% reduction in GHG emissions intensity, transition to 100% renewable energy at 9 sites, and workplace diversity advancements. Repligen also reinforced cybersecurity and governance practices, with active survey participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
none
-
News
Repligen Announces Publication of the Company’s 2022 Sustainability Report
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) announced the digital publication of its 2022 Sustainability Report, highlighting measurable progress in environmental, social, and governance initiatives. The report includes disclosures against Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), UN SDGs, and Task Force on Climate-Related Disclosures (TCFD). The company aims to lower total GHG emissions in alignment with the latest climate science by year end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
none
-
News
Repligen Corporation to Present at Upcoming Investor Conferences
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) will present at the Stifel 2023 Healthcare Conference on November 15 and Stephens’ Annual Investment Conference on November 16. CEO Tony J. Hunt will participate in analyst-led discussions at both events, with live webcasts available on Repligen’s Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
conferences
News
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
Rhea-AI Summary
Repligen Corporation has announced the commercial launch of TangenX SC, the industry's first holder-free, self-contained Tangential Flow Filtration (TFF) device. This technology is suitable for the manufacture of biologics, including ADCs, viral vectors, nucleic acids, and lipid nanoparticles. TangenX SC offers advantages such as significant time savings, reduced risk of product loss, scalability, and single-use, gamma sterilized design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
none
Stock RGEN logo
Repligen Corp.

Nasdaq:RGEN

RGEN Rankings

#843 Ranked by Market Cap
#4078 Ranked by Stock Gains
N/A Ranked by Dividends

RGEN Stock Data

9.58B
51.95M
6.59%
105.58%
8.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Waltham

About RGEN

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.